Last reviewed · How we verify
KRT-232
Inhibits CDK4/6
Inhibits CDK4/6 Used for Myeloproliferative neoplasms.
At a glance
| Generic name | KRT-232 |
|---|---|
| Also known as | navtemadlin |
| Sponsor | Kartos Therapeutics, Inc. |
| Drug class | CDK4/6 inhibitor |
| Target | CDK4/6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
KRT-232 is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which play a critical role in the progression of the cell cycle.
Approved indications
- Myeloproliferative neoplasms
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (PHASE1)
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (PHASE1)
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (PHASE3)
- Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (PHASE1)
- Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer (PHASE2, PHASE3)
- Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |